A Glycomimetic Compound Inhibits DC-SIGN Mediated HIV Infection in Cellular and Cervical Explant Models

Objective: DC-SIGN participates in the initial stages of sexually transmitted HIV-1 infection by recognizing highly mannosylated structures presented in multiple copies on HIV-1 gp120 and promoting virus dissemination. Inhibition of HIV interaction with DC-SIGN thus represents a potential therapeutic approach for viral entry inhibition at the mucosal level. Design: Herein we evaluate the efficacy in inhibiting HIV-1 infection and the potential toxicity of a multimeric glycomimetic DC-SIGN ligand (Dendron 12). Methods: The ability of Dendron 12 to block HIV-1 infection was assessed in cellular and human cervical explant models. Selectivity of Dendron 12 towards DC-SIGN and Langerin was evaluated by Surface Plasmon Resonance studies. β chemokines production following stimulation with Dendron 12 was also analyzed. Toxicity of the compound was evaluated in cellular and tissue models. Results: Dendron 12 averted HIV-1 trans infection of CD4+ T lymphocytes in presence of elevated viral loads and prevented HIV-1 infection of human cervical tissues, under conditions mimicking compromised epithelial integrity, by multiple clades of R5 and X4 tropic viruses. Treatment with Dendron 12 did not interfere with the activity of Langerin and also significantly elicited the production of the β chemokines MIP-1α, MIP-1β and RANTES. Conclusion: Dendron 12, thus, inhibits HIV-1 infection by competition with binding of HIV to DC-SIGN and stimulation of β chemokines production. Dendron 12 represents a promising lead compound for the development of anti-HIV topical microbicides.